<DOC>
	<DOC>NCT01332448</DOC>
	<brief_summary>Roche and GSK will carry out a meta-analysis of liver function data from trials of orlistat to establish whether there is any indication of liver toxicity. The motivation is a cumulative assessment of drug-induced liver injury (DILI) conducted by the FDA following spontaneous reports of liver toxicity in people taking Xenical or Alli.</brief_summary>
	<brief_title>Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials</brief_title>
	<detailed_description />
	<mesh_term>Orlistat</mesh_term>
	<criteria>1. The trial must be randomized and placebocontrolled 2. The orlistat dose must be 60mg or 120mg 3. Data on ALT or BIL must be available 4. The nominal treatment period must be 16 weeks or longer 1. If crossover trials are found, data from other than the first period will be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Xenical</keyword>
	<keyword>Alli</keyword>
	<keyword>safety</keyword>
	<keyword>meta-analysis</keyword>
	<keyword>liver-function test</keyword>
	<keyword>Roche</keyword>
	<keyword>orlistat</keyword>
</DOC>